Epiprobe yarangije hafi miliyoni 100 z'amafaranga yo gutera inkunga Series B.

Mu minsi ishize, Shanghai Epiprobe Biotechnology Co., Ltd. (bita "Epiprobe") yatangaje ko yarangije hafi miliyoni 100 z'amafaranga y'u Rwanda mu gutera inkunga Series B, ikaba ishoramari hamwe n’ishoramari ry’inganda, imishinga ishora imari ya Leta hamwe n’isosiyete Yiyi Shares (SZ) : 001206).

Epiprobe yashinzwe mu 2018, nk'umuntu ushyigikiye kandi ukanabanza kwipimisha kanseri hakiri kare, ni uruganda rukora ikoranabuhanga ryibanda ku gusuzuma kanseri ya molekile no mu nganda z’ubuvuzi bwuzuye.Epiprobe yubakiye ku itsinda rya mbere ry’inzobere mu bijyanye na epigenetics hamwe n’ubushakashatsi bwimbitse, Epiprobe ikora ubushakashatsi ku bijyanye no kumenya kanseri, ishimangira icyerekezo cyo "kwirinda abantu bose kanseri", yiyemeje gutahura hakiri kare, kwisuzumisha hakiri kare no kuvura kanseri hakiri kare, bityo bigatuma ubuzima bubaho igipimo cy'abarwayi ba kanseri kugirango bazamure ubuzima bw'abaturage bose.

Nyuma yo gucukura imyaka 20, itsinda ryibanze rya Epiprobe ryigenga ryavumbuye ubwigenge bwa kanseri Aligned General Methylated Epiprobes (TAGMe), ikwirakwizwa na kanseri zitandukanye, bityo ikagura cyane murwego rwo gusaba.

Kubijyanye na tekinoroji yo gutahura, pyrosequencing isanzwe ifatwa nk "" igipimo cya zahabu "cyo kumenya methylation, nyamara ikaba ishingiye ku guhinduka kwa bisulfite, ariko ikagaragaza ibitagenda neza nko guhindura imikorere idahwitse, kwangirika kwa ADN byoroshye, ibisabwa cyane kubakoresha, no kwishingikiriza ku bikoresho bifite agaciro.Izi mbogamizi zigabanya imikoreshereze yazo.Epiprobe, binyuze mu gutera imbere mu buhanga, yigenga yateje imbere ikoranabuhanga rishya rya methylation - Me-qPCR itavuwe na bisulfite, igabanya ikiguzi kandi igateza imbere itahura n’imikorere y’amavuriro, bigatuma gutahura byoroshye kandi byoroshye.

Epiprobe, yibanda ku bimenyetso nyamukuru by’isosiyete ikora kanseri n’uburyo bwo kumenya methylation, yakoresheje patenti zirenga 50 zo mu gihugu ndetse n’amahanga, kandi yabonye uburenganzira bwo gushyiraho abafite ipatanti ihamye.

Kugeza ubu, Epiprobe yakoranye cyane n’ibitaro birenga 40 byo mu Bushinwa, birimo ibitaro bya Zhongshan, ibitaro mpuzamahanga by’amahoro n’ubuzima bw’abana, n’ibitaro bya Changhai n'ibindi, kandi yashyize mu bikorwa ibicuruzwa byinshi muri kanseri y’imyororokere y’abagore (harimo na kanseri y'inkondo y'umura, kanseri ya endometinal) , kanseri ya urothelia (harimo kanseri y'uruhago, kanseri y'inkari, kanseri y'impyiko), kanseri y'ibihaha, kanseri ya tiroyide, kanseri y'amaraso n'izindi kanseri.Kwemeza impumyi ebyiri byashyizwe mubikorwa 70.000 byamavuriro hamwe na kanseri 25 zose.

Mu bicuruzwa, ku bicuruzwa by’imyororokere y’imyororokere y’umugore, kwemeza impumyi ebyiri byashyizwe mu bikorwa mu mavuriro arenga 40.000, kandi ubushakashatsi bwakozwe bwashyizwe ahagaragara mu binyamakuru bizwi cyane ku rwego mpuzamahanga nk’ubushakashatsi bwa Kanseri, Ubuvuzi bwa Clinical na Translational Medicine, na ibigeragezo byinshi binini-bigeragezwa byamavuriro birashyirwa mubikorwa.Uko iterambere rya R&D ritera imbere kandi umutungo uhora wiyongera, umuyoboro wibicuruzwa byikigo uragenda wiyongera.

Madamu Hua Lin, umuyobozi mukuru wa Epiprobe yagize ati: “Twishimiye kumenyekana no gushyigikirwa n’umurwa mukuru w’inganda.Epiprobe irangwa no kuba yarize cyane mu masomo, ikoranabuhanga ridasanzwe, n'ubushakashatsi bukomeye bwo mu mavuriro, bwatsindiye amashyaka menshi.Mu myaka ine ishize, itsinda ryikigo nibikorwa byateye imbere cyane.Mu minsi iri imbere, ntituzigera dushyira ingufu mu gutumira abafatanyabikorwa bahuje ibitekerezo gufatanya no gukorana, bityo tugahora dutezimbere gahunda yo gusaba R&D no kwiyandikisha, ndetse no guha abaganga n’abarwayi serivisi nziza zo gupima kanseri kandi ibicuruzwa. ”